Docusate

證據等級: L5

預測適應症: 2 個

Docusate: From No Recorded Original Indication to Plummer-Vinson Syndrome

One-Sentence Summary

Docusate (DrugBank ID: DB11089) currently has no recorded original indication, marketing authorization, or mechanism-of-action data in this evidence pack — it is not marketed in the reference regulatory jurisdiction (0 licenses). The TxGNN model predicts a possible association with Plummer-Vinson syndrome, but this signal is supported by 0 clinical trials and 0 publications, meaning it currently rests entirely on knowledge-graph topology rather than any actual clinical or mechanistic evidence.

Quick Overview

Item	Content
Original Indication	Not available — no licenses or original indication text on record
Predicted New Indication	Plummer-Vinson syndrome
TxGNN Prediction Score	99.18%
Evidence Level	L5 (model prediction only, no supporting studies)
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for docusate in this evidence pack (flagged as a High-severity data gap, DG002). Based on the information that is available, docusate is known to function as an intestinally-acting anionic surfactant (stool softener) that lowers stool surface tension to promote water penetration, with minimal systemic absorption.

Plummer-Vinson syndrome is characterized by iron-deficiency anemia, esophageal webs, and dysphagia — a pathology rooted in iron metabolism and mucosal atrophy. There is no known pharmacological overlap between docusate’s local intestinal surfactant action and the iron-metabolism/mucosal mechanisms underlying Plummer-Vinson syndrome.

Because the original mechanism-of-action data is missing and no drug-disease mechanistic bridge can be constructed, this prediction should be interpreted as a topological similarity inference from the TxGNN knowledge graph rather than a mechanism-driven hypothesis. The high prediction score may reflect sparse node connectivity or node-degree bias in the graph rather than genuine pharmacological plausibility.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

US Market Information

No approved licenses are currently on record for docusate in this dataset (market status: Not Marketed; total licenses: 0).

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA label warnings/contraindications and drug-drug interaction data are flagged as a Blocking-severity data gap, DG001 — this must be resolved before any safety pre-assessment (S1) can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction is at Evidence Level L5 — supported only by the TxGNN model with zero clinical trials and zero publications for Plummer-Vinson syndrome. Combined with missing original indication, mechanism of action, and safety label data, there is currently no basis to advance this candidate beyond exploratory screening.

To proceed, the following is needed:

TFDA package insert (warnings, contraindications, drug interactions) — Blocking gap (DG001)
Confirmed mechanism of action data via DrugBank — High-priority gap (DG002)
Confirmation of docusate’s original approved indication(s) and licensing status
Any preclinical or mechanistic rationale linking intestinal surfactant activity to Plummer-Vinson syndrome pathophysiology, before committing further review resources

Additional note: The evidence pack also lists a second, lower-priority TxGNN prediction — vitamin B12- and folate-independent constitutional megaloblastic anemia (score 99.15%, rank 18472) — which carries the same L5/Hold status for the same reasons (ultra-rare disease, no mechanistic or clinical evidence, likely graph topology artifact). It does not change the overall recommendation.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.